Welcome to OncologyPRO, the home of Esmo’s educational and scientific resources.

Comprehensive next-generation sequencing can identify the primary tumour site in carcinoma of unknown origin, while patients with metastatic solid tumours may benefit from germline testing

Women with BRCA1 or BRCA2 mutations who choose to undergo surgery to prevent ovarian cancer have a reduced risk of breast cancer

Pyrotinib plus capecitabine offers better progression-free survival than lapatinib plus capecitabine for previously treated HER2-positive metastatic breast cancer

Durvalumab plus cisplatin–gemcitabine before surgery followed by adjuvant durvalumab may be feasible for muscle-invasive urothelial carcinoma

Advanced urothelial cancer patients who have received a PD-1 or PD-L1 inhibitor and are unable to have cisplatin may benefit from enfortumab vedotin therapy

Dose-intensified salvage radiotherapy offers no benefit over a conventional regimen for men with rising PSA after radical prostatectomy

SWOG 1500 trial findings point to cabozantinib for the treatment of metastatic papillary kidney cancer

Phase III trial indicates progression-free survival advantage for advanced renal cell carcinoma patients given lenvatinib plus pembrolizumab compared with sunitinib